Recombinant Human Butyrylcholinesterase/BCHE Protein, CF

Catalog #: 6137-CE Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
6137-CE-010

R&D Systems Recombinant Proteins and Enzymes

1 Image

All Butyrylcholinesterase/BCHE Proteins and Enzymes

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human Butyrylcholinesterase/BCHE Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain at 5 μg per lane.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to cleave Butyrylthiocholine. The specific activity is >50,000 pmol/min/μg, as measured under the described conditions.

Source

Chinese Hamster Ovary cell line, CHO-derived human Butyrylcholinesterase/BCHE protein
Met1-Leu602, with a C-terminal 6-His tag

Accession #

P06276

N-terminal Sequence
Analysis

Glu29

Structure / Form

Monomer and disulfide-linked homodimers

Predicted Molecular Mass

66 kDa

SDS-PAGE

90-100 kDa, reducing conditions

Product Datasheets

6137-CE

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

6137-CE

Formulation	Supplied as a 0.2 μm filtered solution in Tris and NaCl.
Shipping	The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 6 months from date of receipt, -70 °C as supplied. 3 months, -70 °C under sterile conditions after opening.

Assay Procedure

Materials

Assay Buffer: 100 mM Sodium Phosphate, pH 7.5
Recombinant Human Butyrylcholinesterase/BCHE (rhBCHE) (Catalog # 6137-CE)
Substrate: Butyrylthiocholine chloride (BTC) (Sigma Catalog # B3128), 20 mM stock in DMSO
5,5’-dithio-bis (2-nitrobenzoic acid) (DTNB) (Sigma Catalog # D8130), 10 mM stock in DMSO
96 well Clear Plate (Costar, Catalog # 92592)
Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent

Dilute rhBCHE to 0.02 µg/mL in Assay Buffer.
Dilute BTC and DTNB to 200 µM final concentrations in deionized water.
Load into plate 50 µL of 0.02 µg/mL rhBCHE and start the reaction by adding 50 µL of the BTC/DTNB mixture to the wells. As a Substrate Blank, load 50 µL of Assay Buffer and 50 µL of the BTC/DTNB mixture.
Read in kinetic mode for 5 minutes at an absorbance of 405 nm.
Calculate specific activity:

Specific Activity (pmol/min/µg) =	Adjusted V_max* (OD/min) x well volume (L) x 10¹² pmol/mol
	ext. coeff (M^-1cm^-1) x path corr.* (cm) x amount of enzyme (µg)

     *Adjusted for Substrate Blank
     **Using the extinction coefficient 13260 M^-1cm^-1
     ***Using the path correction 0.32 cm
     Note: the output of many spectrophotometers is in mOD Per Well:

rhBCHE: 0.001 µg
DTNB and BTC: 100 µM

Reconstitution Calculator

Background: Butyrylcholinesterase/BCHE

Butyrylcholinesterase (BCHE) is a major acetylcholine hydrolyzing enzyme in the circulation (1). Although it is present in significant amounts in human plasma, no endogenous physiological substrate has been described for this enzyme. It can degrade a large number of ester-containing compounds besides acylcholines, including neurotoxic organophosphate esters. Thus, it plays significant pharmacological and toxicological roles. It is thought to be involved in the pathological progression of Alzheimer’s disease (AD) by depleting acetylcholine. In contrast to ACHE, it attenuates amyloid fibril formation in vitro (2). BCHE inhibitors have been used to delay symptoms of AD patients by virtue of their ability to enhance ACH availability (3). Its involvement in the cholinergic anti-inflammatory pathway connects BCHE and ACHE as possible markers of low-grade systemic inflammation observed in Type-2 diabetes, obesity, hypertension, coronary heart disease, and AD (4). BCHE can exist as monomers, dimers, or tetramers (1).

References

Darvesh, S. et al. (2003) Nat. Rev. Neurosci. 4:131.
Diamant, S. et al. (2006) Proc. Nat. Acad. Sci. 103:8628.
Campbell, V. A. and Gowran, A. (2007) Br. J. Pharm. 152:655.
Das, U. N. (2007) Med Sci Monit. 13:RA214.

Entrez Gene IDs

590 (Human); 12038 (Mouse)

Alternate Names

Acylcholine acylhydrolase; BCHE; Butyrylcholine esterase; Butyrylcholinesterase; CHE1; CHE1cholinesterase; Choline esterase II; cholinesterase 1; E1; EC 3.1.1.8; Pseudocholinesterase